PHASE II STUDY OF AVELUMAB IN METASTATIC GASTRONETRO-PANCREATIC （GEP） NEUROENDOCRINE CARCINOMA （NEC, WHO GRADE 3） AS SECOND-LINE TREATMENT AFTER FAILING TO ETOPOSIDE+CISPLATIN: INTEGRATION OF GENOMIC ANALYSIS TO IDENTIFY PREDICTIVE MOLECULAR SUBTYPES: